Breaking News Instant updates and real-time market news.

BABY

Natus Medical

$39.70

-0.45 (-1.12%)

06:04
10/19/16
10/19
06:04
10/19/16
06:04

Natus Medical sees Otometrics acquisition accretive to 2017 earnings

"We now expect our recently announced acquisition of Otometrics to close on January 1, 2017. With Otometrics next year, we look forward to achieving $500 million in revenue, an important milestone for Natus. We expect Otometrics to be accretive to our 2017 earnings with a non-GAAP contribution operating margin goal for the year of 10% and a 2018 goal of 20%," said CEO Hawkins.

  • 19

    Oct

  • 29

    Nov

BABY Natus Medical
$39.70

-0.45 (-1.12%)

10/18/16
ROTH
10/18/16
NO CHANGE
Target $47
ROTH
Buy
Roth Capital remains a buyer of Natus Medical ahead of results
Roth Capital analyst Chris Lewis notes that Natus Medical is expected to release full quarterly earnings on Wednesday, but has already announced a Q3 revenue shortfall. While the analyst is disappointed with the miss, he believes the likely earning accretion from Otometrics acquisition should drive stock upside over the medium to long term. He reiterates a Buy rating and $47 price target on the shares.
10/04/16
BNCH
10/04/16
INITIATION
Target $55
BNCH
Buy
Natus Medical initiated with a Buy at Benchmark
Benchmark analyst Raymond Myers started Natus Medical with a Buy rating and $55 price target.
09/26/16
ROTH
09/26/16
NO CHANGE
Target $47
ROTH
Buy
Otometrics acquisition positive for Natus Medical, says Roth Capital
Roth Capital analyst Chris Lewis notes that Natus Medical announced the acquisition of Otometrics for $145M and an expected Q3 revenue shortfall. While the analyst is disappointed with the shortfall, he believes the main driver is transient in nature and should pass by the beginning of 2017. Further, Lewis sees the Otometrics acquisition as a "meaningful positive" for Natus Medical as it significantly expands the company and should allow it to reach $500M in annual revenues in 2017. He reiterates a Buy rating and $47 price target on the shares.
09/13/16
RAJA
09/13/16
UPGRADE
Target $46
RAJA
Outperform
Natus Medical upgraded to Outperform on earnings power at Raymond James
As previously reported, Raymond James analyst Jayson Bedford upgraded Natus Medical to Outperform from Market Perform with a $46 price target. Bedford recently met with management and came away more confident that capital deployment will be larger than expected, potentially increasing earnings meaningfully and acting as a catalyst for shares. He believes Natus will likely add businesses that are adjacent to their core Neurology and Newborn businesses, and would not be surprised to see it carve out a non-core business from a larger entity.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.